Mark Suett, MB, ChB

Teva UK Limited, Harlow, United Kingdom

  • 3Articles
  • 16.7KReads1
  • 2023–2026Active
  • 13Collaborators
  • 26Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Mark Suett, MB, ChB, is affiliated with Teva UK Limited in Harlow, United Kingdom. His publications from 2023 to 2026 focus on clinical aspects of schizophrenia, schizoaffective disorders, and bipolar disorder. His work includes analyses of treatment patterns and outcomes related to long-acting injectable versus oral antipsychotics, as well as factors influencing the initiation and implementation of atypical long-acting injectable antipsychotic agents in patients with early-phase schizophrenia and bipolar I disorder.

Publications

JCP
Outcomes and Practice Patterns of LAI Versus Oral Antipsychotics Among Patients With Bipolar I Disorder in the US
Original Research

Outcomes and Practice Patterns of LAI Versus Oral Antipsychotics Among Patients With Bipolar I Disorder in the US

March 2, 2026

Long-acting injectable antipsychotics, especially second-generation formulations, are associated with reduced rehospitalization in bipolar I disorder compared to oral antipsychotics.
, , , et al
JCP
LAI Implementation After Schizophrenia Diagnosis
Original Research

LAI Implementation After Schizophrenia Diagnosis

April 19, 2023

Although long-acting injectable antipsychotic agents (LAIs) are effective in preventing relapse, their use in first-episode schizophrenia was low, and LAIs were rarely the first therapy for early-phase schizophrenia.
, , , et al
JCP
Predictors for Initiation of LAIs in Individuals With Early-Phase Schizophrenia
Original Research

Predictors for Initiation of LAIs in Individuals With Early-Phase Schizophrenia

February 13, 2023

Initiation of LAIs was predicted by greater switching of oral antipsychotics and more ED visits. LAIs are often used to respond to relapse rather than prevent it.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe